APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Bevacizumab Biosimilar

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Bevacizumab Biosimilar Industry Growth and Trends Forecast to 2032

Report ID 173970160120 December 2025108 pages

Choose your research edition.

Industry ResearchBevacizumab Biosimilar Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Bevacizumab Biosimilar Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Bevacizumab Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bevacizumab Biosimilar Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Bevacizumab Biosimilar Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Bevacizumab Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Bevacizumab Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Bevacizumab Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bevacizumab Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Bevacizumab Biosimilar include Pfizer, Amgen, Reliance lifesciences, Hetero Drugs, Fujifilm Kyowa Kirin Biologics, Celgene Corporation, Biocon, Bevacizumab and Beaconpharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Bevacizumab Biosimilar market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Bevacizumab Biosimilar market size, estimates, and forecasts are presented in terms of sales volume (K Pairs) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Bevacizumab Biosimilar market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Bevacizumab Biosimilar.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Bevacizumab Biosimilar market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Bevacizumab Biosimilar Market by Company

Pfizer

Amgen

Reliance lifesciences

Hetero Drugs

Fujifilm Kyowa Kirin Biologics

Celgene Corporation

Biocon

Bevacizumab

Beaconpharma

Allergan

Bevacizumab Biosimilar Segment by Type

100mg

400mg

Bevacizumab Biosimilar Segment by Application

Renal Cancer

Breast Cancer

Brain Cancer

Colorectal Cancer

Lung Cancer

Other

Bevacizumab Biosimilar Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Bevacizumab Biosimilar manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Bevacizumab Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 100mg Table 2. Major Company of 400mg Table 3. Global Bevacizumab Biosimilar Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Bevacizumab Biosimilar Sales by Type (2021-2026) & (K Pairs) Table 5. Global Bevacizumab Biosimilar Sales Market Share in Volume by Type (2021-2026) Table 6. Global Bevacizumab Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 7. Global Bevacizumab Biosimilar Sales Market Share in Value by Type (2021-2026) Table 8. Global Bevacizumab Biosimilar Price by Type (2021-2026) & (US$ Million) Table 9. Global Bevacizumab Biosimilar Sales by Type (2027-2032) & (K Pairs) Table 10. Global Bevacizumab Biosimilar Sales Market Share in Volume by Type (2027-2032) Table 11. Global Bevacizumab Biosimilar Sales by Type (2027-2032) & (US$ Million) Table 12. Global Bevacizumab Biosimilar Sales Market Share in Value by Type (2027-2032) Table 13. Global Bevacizumab Biosimilar Price by Type (2027-2032) & (US$ Million) Table 14. North America Bevacizumab Biosimilar Sales by Type (2021-2026) & (K Pairs) Table 15. North America Bevacizumab Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Bevacizumab Biosimilar Sales by Type (2021-2026) & (K Pairs) Table 17. Europe Bevacizumab Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Bevacizumab Biosimilar Sales by Type (2021-2026) & (K Pairs) Table 19. Asia-Pacific Bevacizumab Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Bevacizumab Biosimilar Sales by Type (2021-2026) & (K Pairs) Table 21. Latin America Bevacizumab Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Bevacizumab Biosimilar Sales by Type (2021-2026) & (K Pairs) Table 23. Middle East and Africa Bevacizumab Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 24. Bevacizumab Biosimilar Industry Trends Table 25. Bevacizumab Biosimilar Industry Drivers Table 26. Bevacizumab Biosimilar Industry Opportunities and Challenges Table 27. Bevacizumab Biosimilar Industry Restraints Table 28. Global Bevacizumab Biosimilar Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Bevacizumab Biosimilar Revenue Market Share by Company (2021-2026) Table 30. Global Bevacizumab Biosimilar Sales by Company (2021-2026) & (K Pairs) Table 31. Global Bevacizumab Biosimilar Sales Share by Company (2021-2026) Table 32. Global Bevacizumab Biosimilar Market Price by Company (2021-2026) & (US$ Million) Table 33. Global Bevacizumab Biosimilar Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Bevacizumab Biosimilar Major Company Production Sites and Headquarters Table 35. Global Bevacizumab Biosimilar Company, Product Type & Application Table 36. Global Bevacizumab Biosimilar Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Bevacizumab Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Bevacizumab Biosimilar Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Bevacizumab Biosimilar Sales by Region (2021-2026) & (K Pairs) Table 41. Global Bevacizumab Biosimilar Sales Market Share in Volume by Region (2021-2026) Table 42. Global Bevacizumab Biosimilar Sales by Region (2021-2026) & (US$ Million) Table 43. Global Bevacizumab Biosimilar Sales Market Share in Value by Region (2021-2026) Table 44. Global Bevacizumab Biosimilar Sales (K Pairs), Value (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 45. Global Bevacizumab Biosimilar Sales by Region (2027-2032) & (K Pairs) Table 46. Global Bevacizumab Biosimilar Sales Market Share in Volume by Region (2027-2032) Table 47. Global Bevacizumab Biosimilar Sales by Region (2027-2032) & (US$ Million) Table 48. Global Bevacizumab Biosimilar Sales Market Share in Value by Region (2027-2032) Table 49. Global Bevacizumab Biosimilar Sales (K Pairs), Value (US$ Million), Price (US$ Million) and Gross Margin (2027-2032) Table 50. Global Bevacizumab Biosimilar Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Bevacizumab Biosimilar Sales by Application (2021-2026) & (K Pairs) Table 52. Global Bevacizumab Biosimilar Sales Market Share in Volume by Application (2021-2026) Table 53. Global Bevacizumab Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 54. Global Bevacizumab Biosimilar Sales Market Share in Value by Application (2021-2026) Table 55. Global Bevacizumab Biosimilar Price by Application (2021-2026) & (US$ Million) Table 56. Global Bevacizumab Biosimilar Sales by Application (2027-2032) & (K Pairs) Table 57. Global Bevacizumab Biosimilar Sales Market Share in Volume by Application (2027-2032) Table 58. Global Bevacizumab Biosimilar Sales by Application (2027-2032) & (US$ Million) Table 59. Global Bevacizumab Biosimilar Sales Market Share in Value by Application (2027-2032) Table 60. Global Bevacizumab Biosimilar Price by Application (2027-2032) & (US$ Million) Table 61. North America Bevacizumab Biosimilar Sales by Application (2021-2026) & (K Pairs) Table 62. North America Bevacizumab Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Bevacizumab Biosimilar Sales by Application (2021-2026) & (K Pairs) Table 64. Europe Bevacizumab Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Bevacizumab Biosimilar Sales by Application (2021-2026) & (K Pairs) Table 66. Asia-Pacific Bevacizumab Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Bevacizumab Biosimilar Sales by Application (2021-2026) & (K Pairs) Table 68. Latin America Bevacizumab Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Bevacizumab Biosimilar Sales by Application (2021-2026) & (K Pairs) Table 70. Middle East and Africa Bevacizumab Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Bevacizumab Biosimilar Sales (K Pairs), Revenue (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 74. Pfizer Bevacizumab Biosimilar Product Portfolio Table 75. Pfizer Recent Development Table 76. Amgen Company Information Table 77. Amgen Business Overview Table 78. Amgen Bevacizumab Biosimilar Sales (K Pairs), Revenue (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 79. Amgen Bevacizumab Biosimilar Product Portfolio Table 80. Amgen Recent Development Table 81. Reliance lifesciences Company Information Table 82. Reliance lifesciences Business Overview Table 83. Reliance lifesciences Bevacizumab Biosimilar Sales (K Pairs), Revenue (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 84. Reliance lifesciences Bevacizumab Biosimilar Product Portfolio Table 85. Reliance lifesciences Recent Development Table 86. Hetero Drugs Company Information Table 87. Hetero Drugs Business Overview Table 88. Hetero Drugs Bevacizumab Biosimilar Sales (K Pairs), Revenue (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 89. Hetero Drugs Bevacizumab Biosimilar Product Portfolio Table 90. Hetero Drugs Recent Development Table 91. Fujifilm Kyowa Kirin Biologics Company Information Table 92. Fujifilm Kyowa Kirin Biologics Business Overview Table 93. Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Sales (K Pairs), Revenue (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 94. Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Product Portfolio Table 95. Fujifilm Kyowa Kirin Biologics Recent Development Table 96. Celgene Corporation Company Information Table 97. Celgene Corporation Business Overview Table 98. Celgene Corporation Bevacizumab Biosimilar Sales (K Pairs), Revenue (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 99. Celgene Corporation Bevacizumab Biosimilar Product Portfolio Table 100. Celgene Corporation Recent Development Table 101. Biocon Company Information Table 102. Biocon Business Overview Table 103. Biocon Bevacizumab Biosimilar Sales (K Pairs), Revenue (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 104. Biocon Bevacizumab Biosimilar Product Portfolio Table 105. Biocon Recent Development Table 106. Bevacizumab Company Information Table 107. Bevacizumab Business Overview Table 108. Bevacizumab Bevacizumab Biosimilar Sales (K Pairs), Revenue (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 109. Bevacizumab Bevacizumab Biosimilar Product Portfolio Table 110. Bevacizumab Recent Development Table 111. Beaconpharma Company Information Table 112. Beaconpharma Business Overview Table 113. Beaconpharma Bevacizumab Biosimilar Sales (K Pairs), Revenue (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 114. Beaconpharma Bevacizumab Biosimilar Product Portfolio Table 115. Beaconpharma Recent Development Table 116. Allergan Company Information Table 117. Allergan Business Overview Table 118. Allergan Bevacizumab Biosimilar Sales (K Pairs), Revenue (US$ Million), Price (US$ Million) and Gross Margin (2021-2026) Table 119. Allergan Bevacizumab Biosimilar Product Portfolio Table 120. Allergan Recent Development Table 121. North America Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country (K Pairs): 2021 VS 2025 VS 2032 Table 122. North America Bevacizumab Biosimilar Sales by Country (2021-2026) & (K Pairs) Table 123. North America Bevacizumab Biosimilar Sales Market Share by Country (2021-2026) Table 124. North America Bevacizumab Biosimilar Sales Forecast by Country (2027-2032) & (K Pairs) Table 125. North America Bevacizumab Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 126. North America Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America Bevacizumab Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 128. North America Bevacizumab Biosimilar Market Share by Country (2021-2026) Table 129. North America Bevacizumab Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America Bevacizumab Biosimilar Market Share Forecast by Country (2027-2032) Table 131. Europe Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country (K Pairs): 2021 VS 2025 VS 2032 Table 132. Europe Bevacizumab Biosimilar Sales by Country (2021-2026) & (K Pairs) Table 133. Europe Bevacizumab Biosimilar Sales Market Share by Country (2021-2026) Table 134. Europe Bevacizumab Biosimilar Sales Forecast by Country (2027-2032) & (K Pairs) Table 135. Europe Bevacizumab Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 136. Europe Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe Bevacizumab Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe Bevacizumab Biosimilar Market Share by Country (2021-2026) Table 139. Europe Bevacizumab Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe Bevacizumab Biosimilar Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country (K Pairs): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Bevacizumab Biosimilar Sales by Country (2021-2026) & (K Pairs) Table 143. Asia-Pacific Bevacizumab Biosimilar Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific Bevacizumab Biosimilar Sales Forecast by Country (2027-2032) & (K Pairs) Table 145. Asia-Pacific Bevacizumab Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Bevacizumab Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific Bevacizumab Biosimilar Market Share by Country (2021-2026) Table 149. Asia-Pacific Bevacizumab Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific Bevacizumab Biosimilar Market Share Forecast by Country (2027-2032) Table 151. Latin America Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country (K Pairs): 2021 VS 2025 VS 2032 Table 152. Latin America Bevacizumab Biosimilar Sales by Country (2021-2026) & (K Pairs) Table 153. Latin America Bevacizumab Biosimilar Sales Market Share by Country (2021-2026) Table 154. Latin America Bevacizumab Biosimilar Sales Forecast by Country (2027-2032) & (K Pairs) Table 155. Latin America Bevacizumab Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America Bevacizumab Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America Bevacizumab Biosimilar Market Share by Country (2021-2026) Table 159. Latin America Bevacizumab Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America Bevacizumab Biosimilar Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country (K Pairs): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Bevacizumab Biosimilar Sales by Country (2021-2026) & (K Pairs) Table 163. Middle East and Africa Bevacizumab Biosimilar Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa Bevacizumab Biosimilar Sales Forecast by Country (2027-2032) & (K Pairs) Table 165. Middle East and Africa Bevacizumab Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Bevacizumab Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa Bevacizumab Biosimilar Market Share by Country (2021-2026) Table 169. Middle East and Africa Bevacizumab Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa Bevacizumab Biosimilar Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Bevacizumab Biosimilar Distributors List Table 174. Bevacizumab Biosimilar Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Bevacizumab Biosimilar Image Figure 2. Global Bevacizumab Biosimilar Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bevacizumab Biosimilar Market Size (2021-2032) & (US$ Million) Figure 4. Global Bevacizumab Biosimilar Sales (2021-2032) & (K Pairs) Figure 5. 100mg Image Figure 6. Global 100mg Sales YoY Growth (2021-2032) & (K Pairs) Figure 7. 400mg Image Figure 8. Global 400mg Sales YoY Growth (2021-2032) & (K Pairs) Figure 9. Global Bevacizumab Biosimilar Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Bevacizumab Biosimilar Market Share by Type 2025 VS 2032 Figure 11. North America Bevacizumab Biosimilar Sales Market Share in Volume by Type in 2025 Figure 12. North America Bevacizumab Biosimilar Sales Market Share in Value by Type in 2025 Figure 13. Europe Bevacizumab Biosimilar Sales Market Share in Volume by Type in 2025 Figure 14. Europe Bevacizumab Biosimilar Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Bevacizumab Biosimilar Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Bevacizumab Biosimilar Sales Market Share in Value by Type in 2025 Figure 17. Latin America Bevacizumab Biosimilar Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Bevacizumab Biosimilar Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Bevacizumab Biosimilar Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Bevacizumab Biosimilar Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Bevacizumab Biosimilar Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Renal Cancer Image Figure 24. Global Renal Cancer Sales YoY Growth (2021-2032) & (K Pairs) Figure 25. Breast Cancer Image Figure 26. Global Breast Cancer Sales YoY Growth (2021-2032) & (K Pairs) Figure 27. Brain Cancer Image Figure 28. Global Brain Cancer Sales YoY Growth (2021-2032) & (K Pairs) Figure 29. Colorectal Cancer Image Figure 30. Global Colorectal Cancer Sales YoY Growth (2021-2032) & (K Pairs) Figure 31. Lung Cancer Image Figure 32. Global Lung Cancer Sales YoY Growth (2021-2032) & (K Pairs) Figure 33. Other Image Figure 34. Global Other Sales YoY Growth (2021-2032) & (K Pairs) Figure 35. Global Bevacizumab Biosimilar Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Bevacizumab Biosimilar Market Share by Application 2025 VS 2032 Figure 37. North America Bevacizumab Biosimilar Sales Market Share in Volume by Application in 2025 Figure 38. North America Bevacizumab Biosimilar Sales Market Share in Value by Application in 2025 Figure 39. Europe Bevacizumab Biosimilar Sales Market Share in Volume by Application in 2025 Figure 40. Europe Bevacizumab Biosimilar Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Bevacizumab Biosimilar Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Bevacizumab Biosimilar Sales Market Share in Value by Application in 2025 Figure 43. Latin America Bevacizumab Biosimilar Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Bevacizumab Biosimilar Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Bevacizumab Biosimilar Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Bevacizumab Biosimilar Sales Market Share in Value by Application in 2025 Figure 47. North America Bevacizumab Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Pairs) Figure 48. North America Bevacizumab Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Bevacizumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Bevacizumab Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Bevacizumab Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Pairs) Figure 52. Europe Bevacizumab Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Bevacizumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Bevacizumab Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Bevacizumab Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Pairs) Figure 56. Asia-Pacific Bevacizumab Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Bevacizumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Bevacizumab Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Bevacizumab Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Pairs) Figure 60. Latin America Bevacizumab Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Bevacizumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Bevacizumab Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Bevacizumab Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Pairs) Figure 64. Middle East and Africa Bevacizumab Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Bevacizumab Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Bevacizumab Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Bevacizumab Biosimilar Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Bevacizumab Biosimilar Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg
  • 400mg
Applications
  • Renal Cancer
  • Breast Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Other
Companies covered
  • Pfizer
  • Amgen
  • Reliance lifesciences
  • Hetero Drugs
  • Fujifilm Kyowa Kirin Biologics
  • Celgene Corporation
  • Biocon
  • Bevacizumab
  • Beaconpharma
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Bevacizumab Biosimilar Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Bevacizumab Biosimilar Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Bevacizumab Biosimilar Market by Type
  6. 1.3.1 100mg
  7. 1.3.2 400mg
  8. 1.4 Global Bevacizumab Biosimilar Market Size by Type
  9. 1.4.1 Global Bevacizumab Biosimilar Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Bevacizumab Biosimilar Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Bevacizumab Biosimilar Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Bevacizumab Biosimilar Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Bevacizumab Biosimilar Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Bevacizumab Biosimilar Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Bevacizumab Biosimilar Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Bevacizumab Biosimilar Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Bevacizumab Biosimilar Industry Trends
  2. 2.2 Bevacizumab Biosimilar Industry Drivers
  3. 2.3 Bevacizumab Biosimilar Industry Opportunities and Challenges
  4. 2.4 Bevacizumab Biosimilar Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Bevacizumab Biosimilar Revenue (2021-2026)
  2. 3.2 Global Top Players by Bevacizumab Biosimilar Sales (2021-2026)
  3. 3.3 Global Top Players by Bevacizumab Biosimilar Price (2021-2026)
  4. 3.4 Global Bevacizumab Biosimilar Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Bevacizumab Biosimilar Major Company Production Sites & Headquarters
  6. 3.6 Global Bevacizumab Biosimilar Company, Product Type & Application
  7. 3.7 Global Bevacizumab Biosimilar Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Bevacizumab Biosimilar Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Bevacizumab Biosimilar Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Bevacizumab Biosimilar Tier 1, Tier 2, and Tier 3
4 Bevacizumab Biosimilar Regional Status and Outlook
  1. 4.1 Global Bevacizumab Biosimilar Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Bevacizumab Biosimilar Historic Market Size by Region
  3. 4.2.1 Global Bevacizumab Biosimilar Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Bevacizumab Biosimilar Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Bevacizumab Biosimilar Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Bevacizumab Biosimilar Forecasted Market Size by Region
  7. 4.3.1 Global Bevacizumab Biosimilar Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Bevacizumab Biosimilar Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Bevacizumab Biosimilar Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Bevacizumab Biosimilar by Application
  1. 5.1 Bevacizumab Biosimilar Market by Application
  2. 5.1.1 Renal Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Brain Cancer
  5. 5.1.4 Colorectal Cancer
  6. 5.1.5 Lung Cancer
  7. 5.1.6 Other
  8. 5.2 Global Bevacizumab Biosimilar Market Size by Application
  9. 5.2.1 Global Bevacizumab Biosimilar Market Size Overview by Application (2021-2032)
  10. 5.2.2 Global Bevacizumab Biosimilar Historic Market Size Review by Application (2021-2026)
  11. 5.2.3 Global Bevacizumab Biosimilar Forecasted Market Size by Application (2027-2032)
  12. 5.3 Key Regions Market Size by Application
  13. 5.3.1 North America Bevacizumab Biosimilar Sales Breakdown by Application (2021-2026)
  14. 5.3.2 Europe Bevacizumab Biosimilar Sales Breakdown by Application (2021-2026)
  15. 5.3.3 Asia-Pacific Bevacizumab Biosimilar Sales Breakdown by Application (2021-2026)
  16. 5.3.4 South America Bevacizumab Biosimilar Sales Breakdown by Application (2021-2026)
  17. 5.3.5 Middle East and Africa Bevacizumab Biosimilar Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Pfizer
  2. 6.1.1 Pfizer Company Information
  3. 6.1.2 Pfizer Business Overview
  4. 6.1.3 Pfizer Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Pfizer Bevacizumab Biosimilar Product Portfolio
  6. 6.1.5 Pfizer Recent Developments
  7. 6.2 Amgen
  8. 6.2.1 Amgen Company Information
  9. 6.2.2 Amgen Business Overview
  10. 6.2.3 Amgen Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Amgen Bevacizumab Biosimilar Product Portfolio
  12. 6.2.5 Amgen Recent Developments
  13. 6.3 Reliance lifesciences
  14. 6.3.1 Reliance lifesciences Company Information
  15. 6.3.2 Reliance lifesciences Business Overview
  16. 6.3.3 Reliance lifesciences Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Reliance lifesciences Bevacizumab Biosimilar Product Portfolio
  18. 6.3.5 Reliance lifesciences Recent Developments
  19. 6.4 Hetero Drugs
  20. 6.4.1 Hetero Drugs Company Information
  21. 6.4.2 Hetero Drugs Business Overview
  22. 6.4.3 Hetero Drugs Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Hetero Drugs Bevacizumab Biosimilar Product Portfolio
  24. 6.4.5 Hetero Drugs Recent Developments
  25. 6.5 Fujifilm Kyowa Kirin Biologics
  26. 6.5.1 Fujifilm Kyowa Kirin Biologics Company Information
  27. 6.5.2 Fujifilm Kyowa Kirin Biologics Business Overview
  28. 6.5.3 Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Fujifilm Kyowa Kirin Biologics Bevacizumab Biosimilar Product Portfolio
  30. 6.5.5 Fujifilm Kyowa Kirin Biologics Recent Developments
  31. 6.6 Celgene Corporation
  32. 6.6.1 Celgene Corporation Company Information
  33. 6.6.2 Celgene Corporation Business Overview
  34. 6.6.3 Celgene Corporation Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Celgene Corporation Bevacizumab Biosimilar Product Portfolio
  36. 6.6.5 Celgene Corporation Recent Developments
  37. 6.7 Biocon
  38. 6.7.1 Biocon Company Information
  39. 6.7.2 Biocon Business Overview
  40. 6.7.3 Biocon Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Biocon Bevacizumab Biosimilar Product Portfolio
  42. 6.7.5 Biocon Recent Developments
  43. 6.8 Bevacizumab
  44. 6.8.1 Bevacizumab Company Information
  45. 6.8.2 Bevacizumab Business Overview
  46. 6.8.3 Bevacizumab Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bevacizumab Bevacizumab Biosimilar Product Portfolio
  48. 6.8.5 Bevacizumab Recent Developments
  49. 6.9 Beaconpharma
  50. 6.9.1 Beaconpharma Company Information
  51. 6.9.2 Beaconpharma Business Overview
  52. 6.9.3 Beaconpharma Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Beaconpharma Bevacizumab Biosimilar Product Portfolio
  54. 6.9.5 Beaconpharma Recent Developments
  55. 6.10 Allergan
  56. 6.10.1 Allergan Company Information
  57. 6.10.2 Allergan Business Overview
  58. 6.10.3 Allergan Bevacizumab Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Allergan Bevacizumab Biosimilar Product Portfolio
  60. 6.10.5 Allergan Recent Developments
7 North America by Country
  1. 7.1 North America Bevacizumab Biosimilar Sales by Country
  2. 7.1.1 North America Bevacizumab Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Bevacizumab Biosimilar Sales by Country (2021-2026)
  4. 7.1.3 North America Bevacizumab Biosimilar Sales Forecast by Country (2027-2032)
  5. 7.2 North America Bevacizumab Biosimilar Market Size by Country
  6. 7.2.1 North America Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Bevacizumab Biosimilar Market Size by Country (2021-2026)
  8. 7.2.3 North America Bevacizumab Biosimilar Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Bevacizumab Biosimilar Sales by Country
  2. 8.1.1 Europe Bevacizumab Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Bevacizumab Biosimilar Sales by Country (2021-2026)
  4. 8.1.3 Europe Bevacizumab Biosimilar Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Bevacizumab Biosimilar Market Size by Country
  6. 8.2.1 Europe Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Bevacizumab Biosimilar Market Size by Country (2021-2026)
  8. 8.2.3 Europe Bevacizumab Biosimilar Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Bevacizumab Biosimilar Sales by Country
  2. 9.1.1 Asia-Pacific Bevacizumab Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Bevacizumab Biosimilar Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Bevacizumab Biosimilar Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Bevacizumab Biosimilar Market Size by Country
  6. 9.2.1 Asia-Pacific Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Bevacizumab Biosimilar Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Bevacizumab Biosimilar Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Bevacizumab Biosimilar Sales by Country
  2. 10.1.1 South America Bevacizumab Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Bevacizumab Biosimilar Sales by Country (2021-2026)
  4. 10.1.3 South America Bevacizumab Biosimilar Sales Forecast by Country (2027-2032)
  5. 10.2 South America Bevacizumab Biosimilar Market Size by Country
  6. 10.2.1 South America Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Bevacizumab Biosimilar Market Size by Country (2021-2026)
  8. 10.2.3 South America Bevacizumab Biosimilar Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Bevacizumab Biosimilar Sales by Country
  2. 11.1.1 Middle East and Africa Bevacizumab Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Bevacizumab Biosimilar Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Bevacizumab Biosimilar Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Bevacizumab Biosimilar Market Size by Country
  6. 11.2.1 Middle East and Africa Bevacizumab Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Bevacizumab Biosimilar Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Bevacizumab Biosimilar Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Bevacizumab Biosimilar Value Chain Analysis
  2. 12.1.1 Bevacizumab Biosimilar Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Bevacizumab Biosimilar Production Mode & Process
  7. 12.2 Bevacizumab Biosimilar Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Bevacizumab Biosimilar Distributors
  10. 12.2.3 Bevacizumab Biosimilar Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst